Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency

Neurology

Volumn 79, Issue 5, 2012, Pages 435-441

  Stamelou, Maria ^a   Mencacci, Niccolo E ^a,c   Cordivari, Carla ^b   Batla, Amit ^a   Wood, Nick W ^a   Houlden, Henry ^a   Hardy, John ^a   Bhatia, Kailash P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; ROPINIROLE; SELEGILINE; TYROSINE 3 MONOOXYGENASE;

ABSENCE OF SIDE EFFECTS; ADULT; ALLELE; ARTICLE; CEREBRAL PALSY; CLINICAL ARTICLE; CLINICAL EXAMINATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; EVOKED SOMATOSENSORY RESPONSE; EXON; FEMALE; GENETIC ANALYSIS; HETEROZYGOSITY; HUMAN; LUMBAR PUNCTURE; MALE; MYOCLONUS DYSTONIA; PERIPHERAL EDEMA; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SCOLIOSIS; SIDE EFFECT; SPINE FUSION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84866087908     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318261714a     Document Type: Article

References (40)

1. Brautigam C, Wevers RA, Jansen RJT, et al. Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin Chem 1998;44:1897-1904.
2. Willemsen MA, Verbeek MM, Kamsteeg EJ, et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 2010;133: 1810-1822.
3. Brautigam C, Steenbergen-Spanjers GCH, Hoffmann GF, et al. Biochemical and molecular genetic characteristics of the severe form of tyrosine hydroxylase deficiency. Clin Chem 1999;45:2073-2078.
4. De Lonlay P, Nassogne MC, van Gennip AH, et al. Tyrosine hydroxylase deficiency unresponsive to L-dopa treatment with unusual clinical and biochemical resentation. J Inherit Metab Dis 2000;23:819-825.
5. de Rijk-van Andel JF, Gabreels FJM, Geurtz B, et al. L-dopa-responsive infantile hypokinetic rigid parkinsonism due to tyrosine hydroxylase deficiency. Neurology 2000;55:1926-1928.
6. Diepold K, Schutz B, Rostasy K, et al. Levodopa-responsive infantile parkinsonism due to a novel mutation in the tyrosine hydroxylase gene and exacerbation by viral infections. Mov Disord 2005;20:764-767.
7. Zafeiriou DI, Willemsen MA, Verbeek MM, Vargiami E, Ververi A, Wevers R. Tyrosine hydroxylase deficiency with severe clinical course. Mol Genet Metab 2009;97:18-20.
8. Ribases M, Serrano M, Fernandez-Alvarez E, et al. A homozygous tyrosine hydroxylase gene promoter mutation in a patient with dopa-responsive encephalopathy: clinical, biochemical and genetic analysis. Mol Genet Metab 2007; 92:274-277.
9. Verbeek MM, Steenbergen-Spanjers GC, Willemsen MA, et al. Mutations in the cyclic adenosine monophosphate response element of the tyrosine hydroxylase gene. Ann Neurol 2007;62:422-426.
10. Hoffmann GF, Assmann B, Brautigam C, et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol 2003;54: S56-S65.
11. Saunders-Pullman R, Shriberg J, Heiman G, et al. Myoclonus dystonia: possible association with obsessivecompulsive disorder and alcohol dependence. Neurology 2002;58:242-245.
12. Asmus F, Langseth A, Doherty E, et al. "Jerky" dystonia in children: spectrum of phenotypes and genetic testing. Mov Disord 2009;24:702-709.
13. Hess CW, Raymond D, Aguiar Pde C, et al. Myoclonusdystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology 2007;68: 522-524.
14. Han F, Racacho L, Lang AE, Bulman DE, Grimes DA. Refinement of the DYT15 locus in myoclonus dystonia. Mov Disord 2007;22:888-892.
15. Schule B, Kock N, Svetel M, et al. Genetic heterogeneity in ten families with myoclonus-dystonia. J Neurol Neurosurg Psychiatry 2004;75:1181-1185.
16. Nardocci N, Zorzi G, Barzaghi C, et al. Myoclonusdystonia syndrome: clinical presentation, disease course, and genetic features in 11 families. Mov Disord 2008;23: 28-34.
17. Asmus F, Salih F, Hjermind LE, et al. Myoclonus-dystonia due to genomic deletions in the epsilon-sarcoglycan gene. Ann Neurol 2005;58:792-797.
18. Marinoni JC, Stevenson RE, Evans JP, Geshuri D, Phelan MC, Schwartz CE. Split foot and developmental retardation associated with a deletion of three microsatellite markers in 7q21.2-q22.1. Clin Genet 1995;47: 90-95.
19. Armstrong MJ, Shah BB, Chen R, Angel MJ, Lang AE. Expanding the phenomenology of benign hereditary chorea: evolution from chorea to myoclonus and dystonia. Mov Disord 2011;26:2296-2297.
20. Leuzzi V, Carducci C, Cardona F, Artiola C, Antonozzi I. Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive myoclonus-dystonia syndrome. Neurology 2002;59:1241-1243.
21. Angelini L, Erba A, Mariotti C, Gellera C, Ciano C, Nardocci N. Myoclonic dystonia as unique presentation of isolated vitamin E deficiency in a young patient. Mov Disord 2002;17:612-614.
22. Clot F, Grabli D, Cazeneuve C, et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with dopa-responsive dystonia. Brain 2009;132:1753-1763.
23. Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis 2009;32:333-342.
24. Garcia-Cazorla A, Duarte S, Serrano M, et al. Mitochondrial diseases mimicking neurotransmitter defects. Mitochondrion 2008;8:273-278.
25. Gouider-Khouja N, Kraoua I, Benrhouma H, Fraj N, Rouissi A. Movement disorders in neuro-metabolic diseases. Eur J Paediatr Neurol 2010;14:304-307.
26. Roze E, Apartis E, Clot F, et al. Myoclonus-dystonia: clinical and electrophysiologic pattern related to SGCE mutations. Neurology 2008;70:1010-1016.
27. Tezenas du Montcel S, Clot F, Vidailhet M, et al. Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic syndromes. J Med Genet 2006;43:394-400.
28. Grattan-Smith PJ, Wevers RA, Steenbergen-Spanjers GC, Fung VSC, Earl J, Wilcken B. Tyrosine hydroxylase deficiency: clinical manifestations of catecholamine insufficiency in infancy. Mov Disord 2002;17:354-359.
29. Wevers RA, de Rijk-van Andel JF, Brautigam C, et al. A review of biochemical and molecular genetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291delC). J Inherit Metab Dis 1999;22:364-373.
30. Yeung WL, Wong VC, Chan KY, et al. Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency. J Child Neurol 2011;26:179-187.
31. Ludecke B, Knappskog PM, Clayton PT, et al. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 1996;5: 1023-1028.
32. Arai R, Karasawa N, Geffard M, Nagatsu I. L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 1995;195:195-198.
33. Arai R, Karasawa N, Nagatsu I. Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Brain Res 1996;706:177-179.
34. Borah A, Mohanakumar KP. Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol 2007;27:985-996.
35. Navailles S, Bioulac B, Gross C, De Deurwaerdere P. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a regiondependent manner in a rat model of Parkinson's disease. Neurobiol Dis 2011;41:585-590.
36. Nagamoto-Combs K, Piech KM, Best JA, Sun B, Tank AW. Tyrosine hydroxylase gene promoter activity is regulated by both cyclic AMP-responsive element and AP1 sites following calcium influx: evidence for cyclic AMPresponsive element binding protein-independent regulation. J Biol Chem 1997;272:6051-6058.
37. Lazaroff M, Patankar S, Yoon SO, Chikaraishi DM. The cyclic AMP response element directs tyrosine hydroxylase expression in catecholaminergic central and peripheral nervous system cell lines from transgenic mice. J Biol Chem 1995;270:21579-21589.
38. Tinti C, Yang C, Seo H, et al. Structure/function relationship of the cAMP response element in tyrosine hydroxylase gene transcription. J Biol Chem 1997;272: 19158-19164.
39. van den Heuvel L, Luiten B, Smeitink JAM, et al. A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-DOPA-responsive dystonia in the Dutch population. Hum Genet 1998;102:644-646.
40. Pons R, Serrano M, Ormazabal A, et al. Tyrosine hydroxylase deficiency in three greek patients with a common ancestral mutation. Mov Disord 2010;25:1086-1090.